



# 2023 NATIONAL SNAPSHOT REPORT

HEPATITIS C:  
STATE OF  
MEDICAID  
ACCESS

Since 2017, The Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR) have fought to ensure that all people living with hepatitis C (HCV) are able to access treatment through our joint work on the Hepatitis C: State of Medicaid Access project.

We're pleased to report our collective advocacy over the last decade has been working. In particular, the ongoing publication of our State of Medicaid Access reports has successfully supported efforts to eliminate treatment restrictions across the nation. Since we began publishing annual reports, 21 states have removed prior authorization requirement for most patients, 33 have either eliminated or reduced their fibrosis restrictions, 36 have loosened their sobriety restrictions, and 35 have scaled back their prescriber restrictions.

We celebrate this significant wave of progress, but our work will not be done until the promise of an HCV cure is an accessible reality for all. It is in that spirit that we bring you our 2023 snapshot of Medicaid access.

---

**Citation:** Center for Health Law and Policy Innovation & National Viral Hepatitis Roundtable, Hepatitis C: State of Medicaid Access (2023), [www.stateofhepc.org](http://www.stateofhepc.org)

**Hepatitis C: State of Medicaid Access** is supported by AbbVie and Gilead Sciences. The methods, research, and conclusions of this project are those of the Center for Health Law and Policy Innovation of Harvard Law School and National Viral Hepatitis Roundtable and do not necessarily reflect the opinions of AbbVie or Gilead Sciences.


**About CHLPI:** The Center for Health Law and Policy Innovation of Harvard Law School advocates for legal, regulatory, and policy reforms to improve the health of marginalized populations, with a focus on the needs of low-income people living with chronic illnesses and disabilities. CHLPI works to expand access to high-quality health care; to reduce health disparities; to develop community advocacy capacity; and to promote more equitable and effective health care systems. CHLPI is a clinical teaching program of Harvard Law School and mentors students to become skilled, innovative, and thoughtful practitioners as well as leaders in health and public health law and policy. For more information, visit [www.chlpi.org](http://www.chlpi.org).

**About NVHR:** The National Viral Hepatitis Roundtable, an initiative of HEP, is a national coalition fighting for an equitable world free of viral hepatitis. NVHR seeks to eliminate viral hepatitis in the United States and improve the lives of those affected through advocacy, education, and support to national, state and local partners. For more information, visit [www.nvhr.org](http://www.nvhr.org).



### OVERALL STATE GRADES

FEBRUARY 2023



**A+ (9):** Colorado, Idaho, Michigan, Missouri, Oklahoma, Rhode Island, Virginia, Washington, Wisconsin

**A (12):** Alaska, California, DC, Hawaii, Indiana, Louisiana, Massachusetts, New Hampshire, New York, Oregon, Pennsylvania, Texas,

**B (11):** Alabama, Arizona, Connecticut, Kansas, Kentucky, Minnesota, Mississippi, North Carolina, Tennessee, Utah, Vermont


**C (12):** Florida, Georgia, Maine, Maryland, Montana, Nevada, New Jersey, New Mexico, Ohio, Puerto Rico, West Virginia, Wyoming

**D (6):** Delaware, Iowa, Nebraska, North Dakota, South Carolina, South Dakota

**F (2):** Arkansas, Illinois



**PRIOR AUTHORIZATION REQUIREMENTS** FEBRUARY 2023




**No Prior Authorization for Most Patients (21):** Alaska, Arizona, California, Colorado, DC, Hawaii, Idaho, Indiana, Louisiana, Massachusetts, Michigan, Missouri, New Hampshire, New York, Oklahoma, Oregon, Rhode Island, Texas, Virginia, Washington, Wisconsin

**Prior Authorization Required (31):** Alabama, Arkansas, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Maine, Maryland, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Jersey, New Mexico, North Carolina, North Dakota, Ohio, Pennsylvania, Puerto Rico, South Carolina, South Dakota, Tennessee, Utah, Vermont, West Virginia, Wyoming



FIBROSIS RESTRICTIONS

FEBRUARY 2023




**No Fibrosis Restrictions (50):** Alabama, Alaska, Arizona, California, Colorado, Connecticut, DC, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

**Fibrosis Restrictions (2):**  
Arkansas, South Dakota



SUBSTANCE USE RESTRICTIONS

FEBRUARY 2023



**No Substance Use Restriction (38):** Alabama, Arizona, California, Colorado, Connecticut, DC, Florida, Georgia, Hawaii, Idaho, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wyoming

**Provider Must Address and/or Counsel Patient About Substance Use Issues Prior to Treatment (8):** Alaska, Illinois, Iowa, Minnesota, Mississippi, Montana, West Virginia, Wisconsin


**Substance Use Restriction Prior to or During Treatment, Including Abstinence and Mandatory SUD Treatment (6):** Arkansas, Delaware, Nebraska, North Dakota, South Carolina, South Dakota





**PRESCRIBER RESTRICTIONS**

FEBRUARY 2023




**No Prescriber Restrictions (46):** Alabama, Alaska, Arizona, California, Colorado, Connecticut, DC, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

**Prescription by or in Consultation with a Specialist (6):** Arkansas, Illinois, Iowa, Nevada, Puerto Rico, South Carolina



RETREATMENT RESTRICTIONS FEBRUARY 2023




**No Retreatment Restrictions (32):** Alaska, Colorado, Connecticut, DC, Hawaii, Idaho, Kansas, Louisiana, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Washington, Wisconsin

**Retreatment Restrictions based on adherence, substance use, or SVR12 documentation (20):** Alabama, Arizona, Arkansas, California, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Maryland, Maine, Montana, Nebraska, New York, North Dakota, Ohio, West Virginia, Wyoming



MANAGED CARE PARITY

FEBRUARY 2023



No Additional Restrictions in Managed Care (25):

Arkansas, Colorado, Florida, Iowa, Kansas, Kentucky, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Montana, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Virginia, Washington

Additional Restrictions and/or Lack of

Transparency in Managed Care (16): Arizona, DC, Delaware, Georgia, Hawaii, Illinois, Maryland, Massachusetts, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, Oregon, Texas, Utah

N/A, State Doesn't Contract With Managed Care (11):

Alabama, Alaska, California, Connecticut, Idaho, Indiana, Maine, Vermont, West Virginia, Wisconsin, Wyoming